These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31936488)

  • 1. Structure-Based Virtual Screening, Molecular Dynamics and Binding Free Energy Calculations of Hit Candidates as ALK-5 Inhibitors.
    Araujo SC; Maltarollo VG; Almeida MO; Ferreira LLG; Andricopulo AD; Honorio KM
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31936488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational analyses of interactions between ALK-5 and bioactive ligands: insights for the design of potential anticancer agents.
    Almeida MO; Costa CHS; Gomes GC; Lameira J; Alves CN; Honorio KM
    J Biomol Struct Dyn; 2018 Nov; 36(15):4010-4022. PubMed ID: 29132261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a urea-based hit compound as a novel inhibitor of transforming growth factor-β type 1 receptor:
    Li Y; Liu S; Wang Z; Wang X; Xu J; Yao K; Zhang R; Lu C; Wu Z; Hu L
    Phys Chem Chem Phys; 2024 Sep; 26(37):24564-24576. PubMed ID: 39268710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2D-QSAR study, molecular docking, and molecular dynamics simulation studies of interaction mechanism between inhibitors and transforming growth factor-beta receptor I (ALK5).
    Jiang MN; Zhou XP; Sun DR; Gao H; Zheng QC; Zhang HX; Liang D
    J Biomol Struct Dyn; 2018 Nov; 36(14):3705-3717. PubMed ID: 29064324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK.
    Kong X; Sun H; Pan P; Zhu F; Chang S; Xu L; Li Y; Hou T
    Phys Chem Chem Phys; 2018 Feb; 20(7):4851-4863. PubMed ID: 29383359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.
    Ni Z; Zhang TC
    J Mol Model; 2015 Jul; 21(7):175. PubMed ID: 26084268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
    Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
    PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective virtual screening strategy focusing on the identification of novel Bruton's tyrosine kinase inhibitors.
    Xiao J; Zhang S; Luo M; Zou Y; Zhang Y; Lai Y
    J Mol Graph Model; 2015 Jul; 60():142-54. PubMed ID: 26043662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Design for ALK-Positive NSCLC: an Integrated Pharmacophore-Based 3D QSAR and Virtual Screening Strategy.
    James N; Shanthi V; Ramanathan K
    Appl Biochem Biotechnol; 2018 May; 185(1):289-315. PubMed ID: 29134510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
    Rathi E; Kumar A; Kini SG
    J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Density Functional Theory and Molecular Simulation Studies for Prioritizing Anaplastic Lymphoma Kinase Inhibitors.
    James N; Shanthi V; Ramanathan K
    Appl Biochem Biotechnol; 2020 Apr; 190(4):1127-1146. PubMed ID: 31712989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation.
    Wu M; Han J; Liu Z; Zhang Y; Huang C; Li J; Li Z
    Life Sci; 2020 Oct; 258():118228. PubMed ID: 32781071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of type I and type II inhibitors of c-Yes kinase using in silico and experimental techniques.
    Ramakrishnan C; Mary Thangakani A; Velmurugan D; Anantha Krishnan D; Sekijima M; Akiyama Y; Gromiha MM
    J Biomol Struct Dyn; 2018 May; 36(6):1566-1576. PubMed ID: 28589758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Akt kinase inhibitors through structure-based virtual screening and their evaluation as potential anticancer agents.
    Chuang CH; Cheng TC; Leu YL; Chuang KH; Tzou SC; Chen CS
    Int J Mol Sci; 2015 Feb; 16(2):3202-12. PubMed ID: 25648320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
    Davare MA; Vellore NA; Wagner JP; Eide CA; Goodman JR; Drilon A; Deininger MW; O'Hare T; Druker BJ
    Proc Natl Acad Sci U S A; 2015 Sep; 112(39):E5381-90. PubMed ID: 26372962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, 3D QSAR modeling and docking of TGF-β type I inhibitors to target cancer.
    Ajay Kumar TV; Athavan AAS; Loganathan C; Saravanan K; Kabilan S; Parthasarathy V
    Comput Biol Chem; 2018 Oct; 76():232-244. PubMed ID: 30077902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico identification of putative bifunctional Plk1 inhibitors by integrative virtual screening and structural dynamics approach.
    Shafique S; Bibi N; Rashid S
    J Theor Biol; 2016 Jan; 388():72-84. PubMed ID: 26493360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual potent c-Met and ALK inhibitors: from common feature pharmacophore modeling to structure based virtual screening.
    Pirhadi S; Damghani T; Avestan MS; Sharifi S
    J Recept Signal Transduct Res; 2020 Aug; 40(4):357-364. PubMed ID: 32126881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based pharmacophore design and virtual screening for novel potential inhibitors of epidermal growth factor receptor as an approach to breast cancer chemotherapy.
    Mahernia S; Hassanzadeh M; Sharifi N; Mehravi B; Paytam F; Adib M; Amanlou M
    Mol Divers; 2018 Feb; 22(1):173-181. PubMed ID: 29197962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.